Ipsen Management

Management criteria checks 3/4

Ipsen's CEO is David Loew, appointed in Jul 2020, has a tenure of 4.42 years. total yearly compensation is €4.36M, comprised of 22.6% salary and 77.4% bonuses, including company stock and options. directly owns 0.061% of the company’s shares, worth €5.46M. The average tenure of the management team and the board of directors is 4.4 years and 11 years respectively.

Key information

David Loew

Chief executive officer

€4.4m

Total compensation

CEO salary percentage	22.6%
CEO tenure	4.4yrs
CEO ownership	0.06%
Management average tenure	4.4yrs
Board average tenure	11yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Loew's remuneration changed compared to Ipsen's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	€664m
Mar 31 2024	n/a	n/a	€641m
Dec 31 2023	€4m	€988k	€617m
Jun 30 2023	n/a	n/a	€406m
Mar 31 2023	n/a	n/a	€500m
Dec 31 2022	€4m	€950k	€593m
Sep 30 2022	n/a	n/a	€656m
Jun 30 2022	n/a	n/a	€719m
Mar 31 2022	n/a	n/a	€675m
Dec 31 2021	€5m	€950k	€631m
Sep 30 2021	n/a	n/a	€626m
Jun 30 2021	n/a	n/a	€622m
Mar 31 2021	n/a	n/a	€585m
Dec 31 2020	€5m	€475k	€548m

Compensation vs Market: David's total compensation ($USD4.55M) is above average for companies of similar size in the UK market ($USD3.47M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Loew (57 yo)

4.4yrs

Tenure

€4,361,753

Compensation

Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020, and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Loew	MD, CEO & Director	4.4yrs	€4.36m	0.061% € 5.5m
Aymeric Le Chatelier	Executive VP & CFO	10.1yrs	€1.02m	no data
Aidan Murphy	Executive VP and Head of Technical Operations	6.9yrs	no data	no data
Francois Garnier	Executive VP of Legal Affairs	10yrs	no data	no data
Regis Mulot	Executive VP & Chief Human Resources Officer	6.8yrs	no data	no data
Dominique Bery	Head of Nordics & Baltics	7.7yrs	no data	no data
Bartosz Bednarz	Executive VP and Head of Global Product & Portfolio Strategy	4.3yrs	no data	no data
Philippe Lopes-Fernandes	Executive VP & Chief Business Officer	4.2yrs	no data	no data
James Levine	President of Fondation Ipsen	no data	no data	no data
Mari Scheiffele	Executive VP & President of International	3.1yrs	no data	no data
Catherine Abi-Habib	Executive VP and Head of Strategy & Transformation	2.8yrs	no data	no data
Sandra Silvestri	Executive VP & Chief Medical Officer	1.6yrs	no data	no data

4.4yrs

Average Tenure

57yo

Average Age

Experienced Management: IPNP's management team is considered experienced (4.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Loew	MD, CEO & Director	4.6yrs	€4.36m	0.061% € 5.5m
Marc M. de Garidel	Non-Executive Chairman	14.1yrs	€600.00k	0.17% € 15.0m
Margaret Liu	Independent Director	7.5yrs	€130.00k	0.00084% € 74.6k
Michèle Ollier	Director	9.6yrs	€65.00k	0.00061% € 54.2k
Karen Witts	Independent Director	2.9yrs	€115.00k	0.00061% € 54.2k
Antoine Flochel	Vice Chairman	19.3yrs	€165.00k	0.0037% € 324.0k
Henri Beaufour	Director	19.3yrs	€36.00k	0% € 0
Anne Beaufour	Director	19.3yrs	€45.00k	26.54% € 2.4b
Carol Xueref	Director	12.5yrs	€115.00k	0.00061% € 54.2k
Philippe Bonhomme	Director	12.9yrs	€95.00k	no data
Piet Wigerinck	Independent Director	6.6yrs	€78.00k	0.00083% € 73.7k
Laetitia Ducroquet	Employees Representative Director	4.1yrs	no data	0.0010% € 89.7k

11.0yrs

Average Tenure

60.5yo

Average Age

Experienced Board: IPNP's board of directors are seasoned and experienced ( 11 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 16:38
End of Day Share Price	2024/12/19 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ipsen S.A. is covered by 35 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Richard Silver	Barclays
Charles Pitman-King	Barclays
Hae Won Na	Berenberg

Ipsen Management

Management criteria checks 3/4

Key information

Recent management updates

Ipsen Announces Executive Changes

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen Appoints Gwenan White as Executive Vice President Communications and Public Affairs

Recent updates

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen Announces Executive Changes

Dividend of €1.20 announced

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Full year 2023 earnings released: EPS: €7.79 (vs €7.20 in FY 2022)

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

New minor risk - Profit margin trend

First half 2023 earnings released: EPS: €2.36 (vs €4.63 in 1H 2022)

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings released: EPS: €7.20 (vs €7.64 in FY 2021)

Full year 2022 earnings released: EPS: €7.20 (vs €7.82 in FY 2021)

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

First half 2022 earnings released

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Upcoming dividend of €1.20 per share

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Ipsen S.A. Proposes Dividend for the Year 2021

Ipsen Announces the Health Canada Approval of Sohonos as the First Treatment for Fibrodysplasia Ossificans Progressiva

Investor sentiment deteriorated over the past week

Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-Submit Following Additional Data Analyses

First half 2021 earnings released: EPS €3.66 (vs €2.65 in 1H 2020)

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Ipsen S.A. Confirms U.S. Fda Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (Fop)

Upcoming dividend of €1.00 per share

Ipsen Opts-In to Join Exelixis, Inc With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results

Full year 2020 earnings released: EPS €6.56 (vs €0.66 loss in FY 2019)

Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo® as First-Line Treatment for Patients Living with Advanced Renal Cell Carcinoma

Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline Autogel (lanreotide)

Ipsen S.A. Announces New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx®

Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living with Renal Cell Carcinoma At ASCO GU 2021

Ipsen Appoints Gwenan White as Executive Vice President Communications and Public Affairs

Ipsen Announces New Analyses of Pivotal Phase III Trial Data Highlight Long Duration of Response for Dysport (Abobotulinumtoxina) in Five Therapeutic Indications

New 90-day low: €67.15

Ipsen S.A. to Report Fiscal Year 2020 Results on Feb 11, 2021